NCT02612298View on ClinicalTrials.gov

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

PHASE4CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 13, 2018

Study Completion Date

September 13, 2018

Conditions
Essential Hypertension
Interventions
DRUG

Arotinolol Hydrochloride

Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.

DRUG

Metoprolol succinate sustained-release tablet

Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.

Trial Locations (1)

100039

China PLA General Hospital, Beijing

All Listed Sponsors
lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT02612298 - Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate | Biotech Hunter | Biotech Hunter